Search Clinical Trials | Froedtert & the Medical College of Wisconsin

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

138 results

A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Nonsmall Cell Lung Cancer (NSCLC)

Researchers have found that sometimes the body’s own immune system may slow down or control cancer growth. Sometimes this natural immune system response stops, and the cancer is not killed by the immune system. Research has shown that, in some patients, cancer cells and immune cells start to express signals that stop the body’s immune system from killing the cancer. New drugs being developed are designed to block these signals and to increase the immune response. Durvalumab and tremelimumab are two of these drugs. Both drugs are antibodies (proteins that are produced by the body’s defense system). Durvalumab given by itself or with tremelimumab may boost the ability of your immune system to detect and fight cancer. Each of these drugs targets a different signal. Durvalumab targets a signal on cancer cells called Programmed Cell Death Ligand 1 (PD-L1) and tremelimumab targets a signal on immune cells called Cytotoxic T-Lymphocyte-associated Antigen 4 (CTLA-4). It is hoped that by blocking these signals, the immune cells will once again be able to prevent or slow down cancer growth.

The vaccine, BI 1361849, also works by stimulating the body’s immune system to fight and destroy cancer cells. There are six different ingredients in the vaccine that each produce a different antibody response to tumor cells. The vaccine is given through an injection into your skin.

Protocol No

LUDWIG-LUD2014-012-VAC

Sub Category

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Phase II Study of PD-1 Inhibition with Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant Chemotherapy

This project is being done to assess the effectiveness of adding the drug Cemiplimab to the standard neoadjuvant chemotherapy regimen in patients with estrogen receptor and/or progesterone receptor positive, HER2 negative, or triple-negative invasive breast cancer.

Protocol No

IIT-CHAUDHARY-PD1-CEMIPLIMAB

Sub Category

Breast Cancers

An Open-label Phase I Dose Finding Trial with BI 891065 Alone and in Combination with BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients with Advanced and/or Metastatic Malignancies

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Protocol No

BI-1379-0001-REFMAL505

Sub Category

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Standard Systemic Therapy +/- Definitive Treatment in Treating Metastatic Prostate Cancer

Protocol No

SWOG-S1802

Sub Category

Prostate and Urologic Cancers

A Multisite Phase IB Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

The study hypothesis is that the combination of pevonedistat, azacitidine, and venetoclax will be effective, safe, and well tolerated in patients with AML.

Protocol No

IIT-ATALLAH-PAVE-AML

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive HER2 Negative Breast Cancer: The ABC Trial

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Protocol No

ALLIANCE-A011502-ABC

Sub Category

Breast Cancers

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Protocol No

HOFFMANN-WO39608-MORPHEUS

Sub Category

Gastrointestinal Cancers

Early Phase/Multiple Disease Site Cancers

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adults Patients With Progressing Desmoid Tumors (DTs) Aggressive Fibromatosis (AF)

Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Protocol No

SPRINGWORKS-NIR-DT-301

Sub Category

Sarcoma

An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, In Subjects with Relapsed or Refractory Multiple Myeloma

Study of JCARH125, BCMA CAR-T Cells in Subjects with Relapsed or Refractory Multiple Myeloma

Protocol No

JUNO-H125001-CAR-T-EVOLVE

Sub Category

Hematologic/Blood Related Cancers

A Multi-Institutional, Phase IV Project to Study the Feasibility of Safely Managing Patients Receiving Induction with Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia (AML) in an Outpatient Environment

Outpatient Patients Receiving Induction With Liposomal Daunorubicin & Cytarabine (CPX-351) for AML

Protocol No

IIT-MICHAELIS-OUTPT-CPX-351

Sub Category

Hematologic/Blood Related Cancers

A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-stage, P16-positive, Non-smoking Associated Oropharyngeal Cancer

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Protocol No

NRG-HN005

Sub Category

Head and Neck Cancers

A Phase 2 Study of Lisocabragene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Agressive B-Cell NHL (017006)

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (Transcend-Pilot-017006)

Protocol No

JUNO-JCAR017-017006

Sub Category

Hematologic/Blood Related Cancers

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With R/R DLBCL

Protocol No

ALLIANCE-A051301-CTN1201

Sub Category

Hematologic/Blood Related Cancers

A Phase 2, Single-Arm Study of Abemaciclib for Treatment of Advanced Soft Tissue and Bone Sarcoma Identified as having CDK Pathway Alteration

Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration

Protocol No

IIT-CHARLSON-BOAST

Sub Category

Sarcoma

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma Having Progressed within One Year of Initial Treatment (KarMMa-2)

An Efficacy and Safety Study of bb2121 in Subjects with rrMM and in Subjects with High-risk MM

Protocol No

CELGENE-BB2121-MM-002-KARMMA2

Sub Category

Hematologic/Blood Related Cancers

A Phase II Randomized Trial Of Olaparib Versus Olaparib Plus Tremelimumab In Platinum-Sensitive Recurrent Ovarian Cancer

To assess how well olaparib with or without tremelimumab works in treating patients with ovarian, fallopian tube, or peritoneal cancer that has come back

Protocol No

NRG-GY021

Sub Category

Gynecologic Cancers

Glioblastoma Adaptive, Global, Innovative Learning Environment

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)

Protocol No

GCAR-GBM-AGILE

Sub Category

Brain and Spine Cancers

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Protocol No

ECOG-EA8143-PROSPER

Sub Category

Prostate and Urologic Cancers

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

Rituximab with or without SCT in Treating Pt with MRD-Neg MCL in First Complete Remission

Protocol No

ECOG-EA4151

Sub Category

Hematologic/Blood Related Cancers

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide OR Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with MM Using MRD To Direct Therapy Duration (DRAMMATIC STUDY)

S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)

Protocol No

SWOG-S1803-CTN-1706-DRAMMATIC

Sub Category

Hematologic/Blood Related Cancers